Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

12 Issues per year


IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046

VolumeIssuePage

Issues

Neurophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine

Konstantinos Makris1 / Demetrios Rizos2 / Nikolaos Kafkas3 / 4

1Clinical Biochemistry Department, KAT General Hospital, Kifissia, Greece

2Hormone Laboratory, 2nd Department of Obstetrics and Gynecology, Medical School, University of Athens, “Aretaieio” Hospital, Athens, Greece

3Cardiology Department, KAT General Hospital, Kifissia, Greece

4Central Laboratories, Diamedica S.A., Athens, Greece

Corresponding author: Dr. Alexander Haliassos, Central Laboratories, Diamedica S.A., 1 Xenias Street, 115 27, Athens, Greece Phone: +30 694 4373473

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 50, Issue 9, Pages 1519–1532, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/cclm-2012-0227, July 2012

Publication History

Received:
2012-04-09
Accepted:
2012-05-29
Published Online:
2012-07-09

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa protein of the lipocalin superfamily. This protein is expressed and secreted by immune cells, hepatocytes, and renal tubular cells in various pathologic states. NGAL has recently generated great interest as an early biomarker of renal injury. However, like many other endogenous biomarkers it is not produced by just one cell type and it exists in more than one molecular form. As recent research has shown different pathological conditions may involved in the production of this molecule. This review summarizes the current knowledge about the biology of NGAL and examines the role of this molecule of acute renal injury as well as in other pathologic conditions like neoplasia, anemia, pregnancy, cardiovascular disease chronic kidney disease and in cardiorenal syndrome. Commercial and research immunoassays are used to measure NGAL in both plasma and urine but these assays are not standardized. The existence of different molecular forms of NGAL and their expression at various disease states further complicates the interpretation of the results. Pre analytical issues and biological variation are also not fully elucidated.

Keywords: biomarkers; kidney injury; lipocalin 2; neutrophil gelatinase-associated lipocalin (NGAL); siderocalin

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.